Cardiovascular and Metabolic Diseases Market Access in China – Managing challenges to harness growing commercial potential

  • OVERVIEW
    • Catalyst
    • Summary
  • EXECUTIVE SUMMARY
    • Scope of the analysis
    • Datamonitor insight into the Chinese cardiovascular and metabolic diseases market
  • OVERVIEW OF THE CHINESE CARDIOVASCULAR AND METABOLIC DISEASES MARKET
    • Key findings
    • Cardiovascular and metabolic disease burden in China
    • Stroke
      • Global historical trends and expected future trends
      • Key drivers
      • Sources
      • Methods and Results
    • Hypertension
      • Global historical trends and expected future trends
      • Key drivers
      • Sources
      • Methods and Results
    • Dyslipidemia
      • Global historical variation and trends and expected future trends
      • Key drivers
      • Sources
      • Methods and Results
    • Diabetes
      • Global historical trends and expected future trends
      • Key drivers
      • Sources
      • Methods and Results
    • Acute myocardial infarction
      • Global historical trends and expected future trends
      • Key drivers
      • Sources
      • Methods and Results
    • Opportunities and threats
      • (Untitled sub-section)
    • Treatment guidelines for key cardiovascular and metabolic diseases in China
      • (Untitled sub-section)
    • Access to therapy
      • (Untitled sub-section)
  • KEY COMPANIES ACTIVE IN THE CHINESE CARDIOVASCULAR AND METABOLIC DISEASES MARKET
    • Key findings
    • Industry overview
    • Multinational corporations
      • Sanofi-Aventis
      • Novo Nordisk
      • Bayer Schering
      • Pfizer
    • Domestic players
      • Beijing Sihuan
      • Lunan
    • Portfolio review of other leading companies
    • Recent deals and alliances in the cardiovascular and metabolic diseases market in China
  • STRATEGIC RECOMMENDATIONS FOR MARKET ACCESS
    • Key findings
    • Key future target indications
      • Hypertension
      • Diabetes
    • SWOT analysis of the Chinese cardiovascular and metabolic diseases market
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • Strategy for market penetration
      • An appreciation of regional variation can help tailor market entry strategies accordingly
      • Patient education programs can help build brand awareness and a wider patient base
      • The establishment of wholly-owned subsidiaries is the most popular strategy for leading pharmaceutical companies
      • Establishing partnerships with domestic companies can facilitate market access
      • Market access strategies must take into account ongoing healthcare reforms
  • BIBLIOGRAPHY
    • Market overview
      • Websites, publications and online articles
      • Press releases
      • Datamonitor reports and products
    • Key companies active in the Chinese cardiovascular and metabolic diseases market
      • Websites, publications and online articles
      • Press releases
      • Datamonitor reports and products
    • Strategic recommendations for market access
      • Websites, publications and online articles
      • Press releases
  • APPENDIX
    • Report methodology
  • TABLES
    • Table: Total incident cases of stroke in China by gender in those aged between 25 and 74, 2010
    • Table: Total prevalent cases of hypertension in China by age and gender in those aged over 20, 2010
    • Table: Definitions of conditions related to dyslipidemia in the China National Nutrition and Health Survey
    • Table: Total prevalent cases of dyslipidemia in China by age and gender in those aged over 20, 2010
    • Table: Total prevalent cases of type 2 diabetes in China by age and gender in those aged over 15, 2010
    • Table: Total incident cases of acute myocardial infarction (AMI) in China by gender in those aged between 20 and 74, 2010-
    • Table: Opportunities and threats in the cardiovascular and metabolic diseases ( CVMDs) market in China, 2011
    • Table: Total medical expenditure for non-infectious chronic diseases in China, 2003
    • Table: Cardiovascular and metabolic disease (CVMD) drugs listed on the National Essential Drug List (NEDL) for selected multinational pharmaceutical companies in China
    • Table: Key rounds of drug price cuts in China, 1997–2010
    • Table: Tiers of blood pressure level and definition of hypertension used in the 2005 Chinese hypertension guidelines
    • Table: Recommendations for the management of ST-segment elevation and non-ST segment elevation MI in China
    • Table: Key multinational cardiovascular and metabolic disease (CVMD) manufacturers in China, 2011
    • Table: Sanofi-Aventis: key marketed cardiovascular and metabolic disease (CVMD) drugs in China, 2011
    • Table: Novo Nordisk: key marketed cardiovascular and metabolic disease (CVMD) drugs in China, 2011
    • Table: Bayer Schering: key marketed cardiovascular and metabolic disease (CVMD) drugs in China, 2011
    • Table: Pfizer: key marketed cardiovascular and metabolic disease (CVMD) drugs in China, 2011
    • Table: Key domestic cardiovascular and metabolic disease (CVMD) players in China, 2011
    • Table: Beijing Sihuan: key marketed cardiovascular and metabolic disease (CVMD) drugs in China, 2011
    • Table: Lunan Pharma: key marketed cardiovascular and metabolic disease (CVMD) drugs in China, 2011
    • Table: Portfolio analysis of other key players in the Chinese cardiovascular and metabolic diseases (CVMDs) market, 2011
    • Table: Key deals and alliances in the Chinese cardiovascular and metabolic disease s (CVMDs) market, 2007–2010
    • Table: SWOT analysis of China as a cardiovascular and metabolic diseases (CVMDs) market, 2011
    • Table: Recent disease awareness programs in China by leading pharmaceutical players in the cardiovascular and metabolic diseases (CVMDs) market
  • FIGURES
    • Figure: Total incident cases of stroke in China by gender (000s) in those aged between 25 and 74, 2010
    • Figure: Total incident cases of stroke in China by urban-rural split (000s) in those aged between 25 and 74, 2010
    • Figure: Total p revalent cases of hypertension in China by age and gender (000s) in those aged over 20, 2010
    • Figure: Total p revalent cases of hypertension in China by urban-rural split (000s) in those aged over 20, 2010
    • Figure: Total p revalent cases of dyslipidemia in China by age and gender (000s) in those aged over 20, 2010
    • Figure: Total p revalent cases of dyslipidemia in China by urban-rural split (000s) in those aged over 20, 2010
    • Figure: Total p revalent cases of type 2 diabetes in China by age and gender (000s) in those aged over 15, 2010
    • Figure: Total p revalent cases of type 2 diabetes in China by urban-rural split (000s) in those aged over 15 2010
    • Figure: Total incident cases of acute myocardial infarction (AMI) in China by gender (000s) in those aged between 20 and 74, 2010
    • Figure: Total incident cases of acute myocardial infarction (AMI) in China by urban-rural split (000s) in those aged between 20 and 74, 2010
    • Figure: Urban daily fat consumption in China in 1982, 1992, and 2002
    • Figure: Percentage of Chinese men and women who were overweight (BMI of ≥25kg/m²) in 2002, 2005, and 2010
    • Figure: Percentage of Chinese men and women who were obese (BMI ≥30kg/m²) in 2002, 2005 and 2010
    • Figure: Treatment algorithm for the management of hypertension in China
    • Figure: Treatment algorithm for the management of type 2 diabetes in China
    • Figure: Treatment algorithm for the management of stroke in China
    • Figure: Treatment algorithm for the management of acute myocardial infarction in the emergency care setting in China
    • Figure: Comparison of daily treatment cost for selected brands and generics in China, 2011
    • Figure: Bayer Schering’s integrated sales and marketing strategy for Glucobay (acarbose) in China
    • Figure: Key locations of M&A targets sought by Asia Pacific-based acquirers, Q1 2007 to Q1 2010
    • Figure: Number of deals in the Chinese cardiovascular and metabolic diseases (CVMDs) market by type, 2007–2010
    • Figure: Percentage of controlled versus uncontrolled patients after hypertensive therapy in China, 2002
    • Figure: China is perceived as the most attractive location in which to perform clinic trials outside the US, 2008
    • Figure: Expenditure and revenue in the private health insurance sector in China, 2006–2009
    • Figure: Application and approval process for the establishment of a joint venture in China

Report

Published by
Datamonitor
Published on
09 Dec 2011
Product code
HC00139-001
Pages
Please wait...

$5700

Multi-user License $14250